# A Phase 2, Multicenter, Open-Label Trial to Evaluate Efficacy and Safety of Subcutaneous (SC) Mosunetuzumab in Previously Untreated Low Tumor Burden Follicular Lymphoma (LTB-FL).

> **NCT07191249** · PHASE2 · NOT_YET_RECRUITING · sponsor: **Tel-Aviv Sourasky Medical Center** · enrollment: 30 (estimated)

## Conditions studied

- Follicular Lymphoma

## Interventions

- **DRUG:** Mosunetuzumab is a bispecific monoclonal antibody targeting CD20 on B cells and CD3 on T cells, redirecting T cells to eliminate malignant B cells.

## Key facts

- **NCT ID:** NCT07191249
- **Lead sponsor:** Tel-Aviv Sourasky Medical Center
- **Sponsor class:** OTHER_GOV
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** NOT_YET_RECRUITING
- **Start date:** 2025-10-10
- **Primary completion:** 2028-04-01
- **Final completion:** 2029-03-01
- **Target enrollment:** 30 (ESTIMATED)
- **Last updated:** 2025-09-24

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07191249

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07191249, "A Phase 2, Multicenter, Open-Label Trial to Evaluate Efficacy and Safety of Subcutaneous (SC) Mosunetuzumab in Previously Untreated Low Tumor Burden Follicular Lymphoma (LTB-FL).". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT07191249. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*